Colchicine is well known for its antimitotic and antiinflammatory effects. This study was designed to evaluate the role of oral colchicine in chronic plaque psoriasis. Fifty adults with chronic plaque psoriasis were randomly allocated into 2 groups of 25 patients each. Group A received oral colchicine 2 mg/day in 2 divided doses, while Group B patients were given placebo tablets. Patients were evaluated every week and the final result compiled after 8 weeks. 90% patients in Group A had gastrointestinal intolerance necessitating a reduction in dose of colchicine to 1 mg/day. After 8 weeks the lesions improved significantly in Group-A patients, compared to Group B (t=2.815, p<0.01). Apart from gastrointestinal intolerance and nephrotic syndrome, no other significant side effects were encountered. It may be worthwhile trying this drug in chronic plaque psoriasis recalcitrant to conventional topical treatment.
|Original language||English (US)|
|Number of pages||4|
|Journal||Indian Journal of Dermatology, Venereology and Leprology|
|Publication status||Published - Dec 1 1993|
ASJC Scopus subject areas
- Infectious Diseases